You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
As per the USFDA guidance of Orlistate,( [https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020766.pdf]
Data from PD study on fecal fat excretion should be analyzed based on dose-scale analysis to
estimate relative bioavailability.
Model is y= E0 + Emax* Dose* Fi/ED50 + (Dose*Fi)
Where y = Response, Dose = Administered dose, E0 = Baseline response in the absence
of the drug, Emax = Fitted maximum drug effect, ED50 = Dose required to produce 50%
the fitted maximum effect, and i = Treatment indicator (0 = Ref, 1 = Test), with the
understanding that F0 = 1 and that F1 is the relative potency used to evaluate
bioequivalence.
The same approach has to be used for albuterol Bronchoprovocation study. [https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020503.pdf]
I am struggling to prepare the dataset and model (snapshot attached) in which have four treatment i,e, placebo, test, reference(2 doses) and from which F- relative bioavailability needs to be calculated
I would suggest changing the independent variable DOSE to time in your dataset and in your model. Perhaps in the future you can declare a different idependent variable in nlmixr but right now it isn't possible.
As per the USFDA guidance of Orlistate,( [https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020766.pdf]
Data from PD study on fecal fat excretion should be analyzed based on dose-scale analysis to
estimate relative bioavailability.
Model is y= E0 + Emax* Dose* Fi/ED50 + (Dose*Fi)
Where y = Response, Dose = Administered dose, E0 = Baseline response in the absence
of the drug, Emax = Fitted maximum drug effect, ED50 = Dose required to produce 50%
the fitted maximum effect, and i = Treatment indicator (0 = Ref, 1 = Test), with the
understanding that F0 = 1 and that F1 is the relative potency used to evaluate
bioequivalence.
The same approach has to be used for albuterol Bronchoprovocation study. [https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_020503.pdf]
I am struggling to prepare the dataset and model (snapshot attached) in which have four treatment i,e, placebo, test, reference(2 doses) and from which F- relative bioavailability needs to be calculated
img.docx
The text was updated successfully, but these errors were encountered: